ATL-1102 is under clinical development by Percheron Therapeutics and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData, Phase II drugs for Duchenne Muscular Dystrophy have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ATL-1102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ATL-1102, (TV-1102, ISIS 107248) is under development for the treatment of relapsing-remitting multiple sclerosis, asthma, Duchenne muscular dystrophy, limb girdle muscular dystrophy R2 and other inflammatory diseases. It is administered through subcutaneous, inhalation route of administration. It is formulated as a solution for multiple sclerosis. ATL1102 is a second-generation antisense inhibitor of CD49d, a subunit of VLA-4 (very late antigen-4). The therapeutic candidate is developed based on antisense technology. It was also under development for the treatment of hematopoietic stem cell transplantation.
It was also under development for acute myeloid leukemia and secondary progressive multiple sclerosis (SPMS).
Percheron Therapeutics overview
Percheron Therapeutics formerly Antisense Therapeutics, is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of second-generation antisense pharmaceuticals. The company focuses on the development of antisense drugs in the areas of immunology disorders and rare diseases such as multiple sclerosis (MS) among others. Percheron Therapeutics’ development pipeline comprises ATL1103 for a potential treatment for growth hormone disorders such as Acromegaly; ATL1102 (injection), which reduces brain lesions is being developed for the treatment of multiple sclerosis. ATL1102 is also being developed for the treatment of duchenne muscular dystrophy (DMD). Percheron Therapeutics is headquartered in Toorak, Victoria, Australia.
For a complete picture of ATL-1102’s drug-specific PTSR and LoA scores, buy the report here.